Wall Street brokerages expect that Constellation Pharmaceuticals Inc (NASDAQ:CNST) will report earnings per share (EPS) of ($0.80) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Constellation Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.82) and the highest is ($0.78). Constellation Pharmaceuticals reported earnings per share of ($9.96) during the same quarter last year, which suggests a positive year over year growth rate of 92%. The business is expected to issue its next earnings report on Tuesday, August 13th.
On average, analysts expect that Constellation Pharmaceuticals will report full-year earnings of ($3.13) per share for the current year, with EPS estimates ranging from ($3.40) to ($2.83). For the next year, analysts anticipate that the business will post earnings of ($3.20) per share, with EPS estimates ranging from ($4.25) to ($2.14). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Constellation Pharmaceuticals.
Constellation Pharmaceuticals (NASDAQ:CNST) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.75) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.05.
Several brokerages recently weighed in on CNST. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Constellation Pharmaceuticals in a research note on Wednesday, June 5th. Oppenheimer lifted their price target on Constellation Pharmaceuticals from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Tuesday, April 2nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.82.
Hedge funds have recently bought and sold shares of the stock. Svennilson Peter acquired a new stake in Constellation Pharmaceuticals in the 4th quarter worth about $18,759,000. Vanguard Group Inc. acquired a new stake in Constellation Pharmaceuticals in the 3rd quarter worth about $989,000. Wade G W & Inc. acquired a new stake in Constellation Pharmaceuticals in the 1st quarter worth about $166,000. Sphera Funds Management LTD. acquired a new stake in Constellation Pharmaceuticals in the 4th quarter worth about $281,000. Finally, Casdin Capital LLC boosted its holdings in Constellation Pharmaceuticals by 18.4% in the 4th quarter. Casdin Capital LLC now owns 1,556,998 shares of the company’s stock worth $6,244,000 after buying an additional 242,255 shares during the last quarter. Institutional investors own 64.38% of the company’s stock.
Shares of Constellation Pharmaceuticals stock traded down $0.02 on Tuesday, hitting $10.05. The company’s stock had a trading volume of 54,945 shares, compared to its average volume of 85,419. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.25. Constellation Pharmaceuticals has a 1 year low of $4.01 and a 1 year high of $14.04. The firm’s fifty day moving average is $9.85.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Read More: Put Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.